Reshma Rangwala - 31 Jan 2026 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP & Chief Medical Officer
Signature
/s/Nancy Smith as Attorney-in-Fact for Reshma Rangwala
Issuer symbol
KPTI
Transactions as of
31 Jan 2026
Net transactions value
$0
Form type
4
Filing time
03 Feb 2026, 16:31:25 UTC
Previous filing
16 Sep 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rangwala Reshma EVP & Chief Medical Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON /s/Nancy Smith as Attorney-in-Fact for Reshma Rangwala 03 Feb 2026 0001825322

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +32,415 +110% $0.000000 61,805 31 Jan 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.